Brand management tools for the development of pharmaceutical companies

Abstract

The article examines brand management tools as a driver of pharmaceutical enterprises’ development under conditions of intense competition, product standardization, and regulatory constraints on marketing communications. The study aims to substantiate and analyze brand management tools that foster the development of pharmaceutical enterprises, as well as to assess their effectiveness based on marketing research. The methodological framework relies on systemic and integrated approaches; the research employs content analysis of academic and regulatory sources, a questionnaire survey of key stakeholder groups (representatives of pharmaceutical enterprises, physicians, and pharmacists), descriptive statistics, and correlation analysis. Brand management tools are systematized by the marketing mix, target audiences, Rx/OTC market segments, and the time horizon of impact. To quantitatively measure the level of brand-related activities, an integrated Brand Activity Index (IBA_j) is proposed and constructed from four blocks of tools: professional communications; consumer communications; digital tools; and interaction with pharmacy chains combined with corporate reputation/social initiatives, followed by normalization to the [0;1] interval. The empirical results show the predominance of professional communications and pharmacy-channel tools in companies’ practices, as well as a statistically significant positive relationship between the integrated brand activity index and sales growth rates, which supports the value of a systematic (rather than fragmented) use of a comprehensive set of tools. The practical value of the findings lies in recommendations for building a balanced toolset, differentiating communications by target audiences, and introducing monitoring of the effectiveness of brand-related activities. The study limitations are related to the size and structure of the sample and partial reliance on self-reports, which indicates the need for further research with an expanded empirical base and more objective market indicators.